Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-11
2010-11-23
Shiao, Rei-tsang (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S324000, C514S320000
Reexamination Certificate
active
07838535
ABSTRACT:
The invention is directed to compounds of formula I:wherein R1, R2, R3, R4, R5, R6, R7a, R7b, W, G1, G2, a, b, c, d and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
REFERENCES:
patent: 5621010 (1997-04-01), Sueda et al.
patent: 5648370 (1997-07-01), Bonnert et al.
patent: 5763465 (1998-06-01), Bonnert et al.
patent: 5846989 (1998-12-01), Bonnert et al.
patent: 5929100 (1999-07-01), Bonnert et al.
patent: 5973167 (1999-10-01), Bonnert et al.
patent: 5977384 (1999-11-01), Bonnert et al.
patent: 6008365 (1999-12-01), Bonnert et al.
patent: 6080869 (2000-06-01), Bonnert et al.
patent: 6433027 (2002-08-01), Bozung et al.
patent: 6635764 (2003-10-01), Mammen et al.
patent: 6693202 (2004-02-01), Aggen et al.
patent: 7094790 (2006-08-01), Cowart et al.
patent: 7345060 (2008-03-01), Mammen et al.
patent: 2003/0018019 (2003-01-01), Meade et al.
patent: 2004/0029919 (2004-02-01), Mammen et al.
patent: 2004/0167167 (2004-08-01), Mammen et al.
patent: 2004/0209860 (2004-10-01), Mammen et al.
patent: 2004/0209915 (2004-10-01), Mammen et al.
patent: 0 005 610 (1979-11-01), None
patent: 0 419 397 (1991-03-01), None
patent: 0 747 355 (1996-12-01), None
patent: 0 863 141 (1998-09-01), None
patent: 0 930 298 (1999-07-01), None
patent: WO 92/08708 (1992-05-01), None
patent: WO 93/20071 (1993-10-01), None
patent: WO 93/23385 (1993-11-01), None
patent: WO 93/24473 (1993-12-01), None
patent: WO 95/06635 (1995-03-01), None
patent: WO 97/10227 (1997-03-01), None
patent: WO 97/23470 (1997-07-01), None
patent: WO 99/09018 (1999-02-01), None
patent: WO 99/31086 (1999-06-01), None
patent: WO 99/64043 (1999-12-01), None
patent: WO 00/50413 (2000-08-01), None
patent: WO 01/11933 (2001-02-01), None
patent: WO 01/12167 (2001-02-01), None
patent: WO 01/12191 (2001-02-01), None
patent: WO 01/12192 (2001-02-01), None
patent: WO 01/42212 (2001-06-01), None
patent: WO 01/42213 (2001-06-01), None
patent: WO 02/06255 (2002-01-01), None
patent: WO 02/051841 (2002-07-01), None
patent: WO 2004/012684 (2004-02-01), None
patent: WO 2004/016601 (2004-02-01), None
Austin et al., “QSAR and the Rational Design of Long-Acting Dual D2-Receptor/β2—Adrenoceptor Agonists”, J. Med. Chem., 46, pp. 3210-3220 (2003).
Birrell et al., “Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD”, British Journal of Pharmacology, 136, pp. 620-628 (2002).
Bonnert et al., “Dual D2-Receptor and β2—Adrenoceptor Agonists for the Treatment of Airway Diseases. 1. Discovery and Biological Evaluation of Some 7-(2-Aminoethyl)-4-hydroxybenzothiazol-2(3H)-one Analogues”, J. Med. Chem. 41, pp. 4915-4917 (1998).
Fozard et al., “Inhibition by viozan of extravasation induced in rat trachea by capsalcin is mediated exclusively by β2-adrenoceptors”, Naunyn-Schmiedeberg's Arch Pharmacol 364: pp. 570-572 (2001).
Graul et al., Viozan™, Drugs of the Future 2000, 25(2): pp. 165-169.
Naito et al., “Selective Muscarinic Antagonists. II.1)Synthesis and Antimuscarinic Properties of Biphenylylcarbamate Derivatives”, Chem. Pharm. Bull. 46(8), pp. 1286-1294 (1998)..
Newbold et al., “Dual D2Dopamine Receptor and β2-Adrenoceptor Agonists for the Modulation of Sensory Nerves in COPD”, Hansel TT, Barnes PJ (eds): New Drugs for Asthma, Allergy and COPD, Prog Respir Res. Basel, Karger, vol. 31, pp. 68-71 (2001).
Suzuki et al., “S1319: A Novel β2-Adrenoceptor Agonist From A Marine SpongeDysidea SP.”, Bioorganic & Medicinal Chemistry Letters 9, pp. 1361-1364 (1999).
Suzuki et al., “The effects of S1319, a novel marine sponge-derived β2-adrenoceptor agonist, on IgE-mediated activation of human cultured mast cells”, Inflamm. res. 49, pp. 086-094 (2000).
Suzuki et al., “Tracheal relaxing effects and β2adrenoceptor selectivity of S1319, a novel sponge-derived bronchodilator agent, in Isolated guinea-pig tissues”, British Journal of Pharmacology, 128, pp. 716-720 (1999).
Weinstock et al., “Synthesis and Evaluation of Non-Catechol D-1 and D-2 Dopamine Receptor Agonists: Benzlmidazol-2-one, Benzoxazol-2-one, and the Highly Potent Benzothiazol-2-one 7-Ethylamines”, J. Med. Chem., 30, pp. 1166-1176 (1987).
Office Action dated Apr. 24, 2007, for U.S. Appl. No. 10/992,927 (now U.S. 7,345,060 B2).
Dunham Sarah
Mammen Mathai
Hagenah Jeffrey A.
Shiao Rei-tsang
Theravance Inc.
LandOfFree
Compounds having β 2 adrenergic receptor agonist and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds having β 2 adrenergic receptor agonist and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds having β 2 adrenergic receptor agonist and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4251386